Showing 1271-1280 of 1717 results for "".
Clinical Trials for Huntington Disease
https://practicalneurology.com/diseases-diagnoses/movement-disorders/clinical-trials-for-huntington-disease/31681/The promise for potential disease-modifying research is strong, although continued discovery uncovers new questions and challenges to overcome.Muscle MRI for Neuromuscular Disorders
https://practicalneurology.com/diseases-diagnoses/neuromuscular/muscle-mri-for-neuromuscular-disorders/31687/Using muscle MRI to diagnose neuromuscular conditions requires awareness of different patterns of muscle involvement.Therapeutic Approaches to Neuromuscular Repeat Disorders: Facioscapulohumeral Muscular Dystrophy and Myotonic Dystrophy Type 1
https://practicalneurology.com/diseases-diagnoses/neuromuscular/therapeutic-approaches-to-neuromuscular-repeat-disorders-facioscapulohumeral-muscular-dystrophy-and-myotonic-dystrophy-type-1/32027/A promising pipeline of therapeutics target toxic RNA.Bruton Tyrosine Kinase Inhibition in Multiple Sclerosis
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/bruton-tyrosine-kinase-inhibition-in-multiple-sclerosis/31872/The missing link for treatment optimization?Special Report: Cognitive Screening After COVID-19
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/special-report-cognitive-screening-after-covid-19/31791/Tools are needed for the assessment of neurologic and neuropsychologic sequelae of infection with the SARS-CoV-2 virus.Health Care Disparities in Alzheimer Disease Diagnosis and the Use of Amyloid-Targeting Treatments
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/health-care-disparities-in-alzheimer-disease-diagnosis-and-the-use-of-amyloid-targeting-treatments/36240/Disparities in Alzheimer disease care persist, and people from underrepresented racial, ethnic, or socioeconomic groups face considerable barriers to early diagnosis and access to disease-modifying anti-amyloid therapies.- News Briefshttps://practicalneurology.com/columns/practice-management/news-briefs/31327/Thousands of neurologists gathered at the San Diego Convention Center from April 1-8 for the American Academy of Neurology’s (AAN) annual conference, fostering extensive collaboration across subspecialties. Among the key highlights were the release of four new evidence-based practice parameters for
- Lifting the Fog: How to Uncover the Cognitive Effects of AEDshttps://practicalneurology.com/columns/practice-management/lifting-the-fog-how-to-uncover-the-cognitive-effects-of-aeds/31142/Impact of Antiepileptic Drugs on Cognitive and Psychiatric Well-BeingIn the management of epilepsy and migraines, antiepileptic drugs (AEDs) play a crucial role in controlling symptoms. However, the long-term and often lifelong use of AEDs can lead to significant cognitive adverse events (CAE) and p
- Leaving AEDs Behind: When to Withdraw Therapy in Seizure-free Patientshttps://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/pn1008_04-pdf/30980/Managing Antiepileptic Drug (AED) Therapy in Seizure-Free Patients: Key ConsiderationsAchieving complete seizure control is the primary objective in epilepsy management, significantly improving patient quality of life. In specific epilepsy syndromes, such as benign rolandic epilepsy (childhood epile
- Six Burning Questions about Diabetic Neuropathyhttps://practicalneurology.com/columns/practice-management/six-burning-questions-about-diabetic-neuropathy/31023/Diabetic Neuropathies: Current Insights and Management StrategiesDiabetic neuropathies are the most prevalent forms of neuropathy globally, presenting significant challenges in clinical management and research. Despite advancements in understanding their clinical manifestations, critical aspects suc